Welcome to Synapse - connecting you with news and analysis on legal and commercial issues in the life sciences.
Licensing out - try not to get benched
When licensing out a product to a bigger player, one of the risks is that the licensed product is shelved and the licensor never sees any revenue from it. As Colin McCall and Justyna Ostrowska explain, this can happen for many reasons, and the licence agreement should anticipate that.
Synapse Toolkit
A legal toolkit for life sciences companies and their investors providing access to information on:
Funding life sciences companies
Duties and liabilities of company directors
Confidentiality and related protection
Supplementary protection certificates
Protecting and enforcing intellectual property
Topical Issues
UK increases scrutiny of tech and life sciences deals - The UK remains an attractive environment for foreign investments. However, as Paolo Palmigiano explains, in recent months, we've seen trends that indicate that mergers and acquisitions in the tech and life sciences sectors may be subject to closer scrutiny by the UK competition authority and by the UK government in future....read more
US buys up entire stock of remdesivir - After the US was reported to have bought the entire stock of remdesivir from producer Gilead, Judith Krens asks whether there are ways to intervene in the Netherlands (and in other European countries)....
read more
Dissecting the Regeneron v Kymab mouse case – what it says and its impact on patents - Adrian Toutoungi, Matthew Royle and Paul England discuss whether this case has shifted the boundaries of patent protection, or merely clarified the status quo....read more
Private equity investment in life sciences sector - Our experts explore some of the potential benefits and challenges for life sciences companies considering private equity investment from the perspective of investee companies, as well as the emerging trends we've identified around the nature of PE investments into the sector....read more
Patent diary – July 2020: Court refuses to strike out Chiesi's quia timet injunction claim - Paul England reports on the Patent Court's refusal to strike out a quia timet injunction claimed by Chiesi against Teva....read more
Subscribe to Synapse
Receive our monthly newsletter keeping you updated on recent developments and events in the Life Sciences sector.
Register here
